Basic Cefuroxime Information

• INN (International Nonproprietary Name): Cefuroxime (Latin: Cefuroximum).
• Brand Names Available In United Kingdom: Zinnat (oral tablets and suspension) and Zinacef (injection vials) are listed as available in the UK.
• ATC Code: J01DC02 (second‑generation cephalosporin); S01AA27 for ophthalmic intracameral use.
• Forms & Dosages: Film‑coated tablets 125 mg, 250 mg and 500 mg; oral suspension (reconstituted granules) 125 mg/5 ml and 250 mg/5 ml; powder for injection vials 750 mg and 1.5 g; intracameral eye injection 1 mg/0.1 ml.
• Manufacturers In United Kingdom: GlaxoSmithKline (GSK) supplies Zinnat/Zinacef; multiple generics are supplied by other manufacturers.
• Registration Status In United Kingdom: Widely authorised in EU markets and marketed in the UK; trade names and indications may differ between territories.
• OTC / Rx Classification: Prescription‑only (Rx) in nearly all markets.

Key Findings From Recent Trials

What do clinicians want to know about cefuroxime trials from 2022 to mid‑2024?

Large pragmatic trials and up‑to‑date systematic reviews reaffirm cefuroxime as a reliable second‑generation cephalosporin for community‑acquired respiratory and skin infections.

Randomised controlled trials and meta‑analyses during 2022–2024 support oral cefuroxime axetil as an effective step‑down after intravenous therapy for selected non‑severe pneumonias and complicated urinary tract infections.

These studies generally showed non‑inferiority of oral step‑down regimens compared with comparator treatments when patients were clinically stable.

Clinical cure rates reported for uncomplicated respiratory and skin infections commonly ranged around 80–90% with standard dosing.

Oral step‑down was associated with shortened hospital stay in pragmatic cohorts without an increase in relapse when selection criteria were followed.

Early Lyme disease trials continued to support the use of 500 mg twice daily for symptom resolution in adults.

Pooled safety outcomes from recent RCTs and surveillance align with historical safety profiles for cefuroxime.

The most frequent adverse events were gastrointestinal upset and mild rash in trial reports.

Large surveillance series noted rare occurrences of a positive Coombs test and occasional Clostridioides difficile cases, highlighting stewardship concerns.

Overall trial conclusions align with EMA and NICE principles favouring targeted, guideline‑concordant prescribing in primary and secondary care.

Clinicians reading these data should consult local susceptibility reports before using cefuroxime for empirical therapy in community settings.

Clinical Mechanism Of Action

How does cefuroxime actually kill bacteria?

Cefuroxime is a beta‑lactam antibiotic that interferes with bacterial cell wall synthesis, causing cell lysis.

It binds to penicillin‑binding proteins and inhibits peptidoglycan cross‑linking in the cell wall.

As a second‑generation cephalosporin (ATC J01DC02), cefuroxime offers improved Gram‑negative activity relative to first‑generation cephalosporins while retaining good streptococcal coverage.

The oral formulation is cefuroxime axetil, a prodrug that is converted to active cefuroxime after absorption.

Food influences cefuroxime axetil absorption and concomitant antacids or gastric acid suppressants can reduce bioavailability.

Intravenous and intramuscular formulations as cefuroxime sodium provide predictable plasma concentrations for severe infections.

Elimination is primarily renal, so dose adjustment is necessary in impaired eGFR to avoid accumulation.

The mechanism and pharmacokinetics explain why cefuroxime is commonly used for ENT and respiratory infections, skin and soft‑tissue infections, and as oral step‑down after IV therapy.

Understanding the axetil prodrug and renal clearance helps prescribers optimise dosing and administration timing in primary care and hospital settings.

Scope Of Approved And Off‑Label Use

Which infections is cefuroxime licensed to treat in the UK and where is it used off‑label?

Licenced indications include tonsillitis, otitis media, sinusitis, lower respiratory tract infections and pneumonia, skin and soft‑tissue infections, and early Lyme disease.

Intravenous formulations are licensed for severe infections, including systemic bacterial infections and certain cases of meningitis as part of hospital care.

Available strengths on the UK market include tablets 125 mg, 250 mg and 500 mg, and injection powder vials of 750 mg and 1.5 g.

Ophthalmic intracameral use is available as 1 mg in 0.1 ml for specific intraocular prophylaxis where licensed.

Common off‑label trends among UK clinicians include oral step‑down from IV cefuroxime and targeted empirical use against suspected beta‑lactamase producing community pathogens.

Historically, single‑dose intramuscular cefuroxime was used for gonorrhoea, but guideline changes and resistance patterns have reduced this practice.

All cefuroxime prescriptions must be issued by a prescriber in line with local formularies and stewardship policies.

Trusts frequently list Zinnat or Zinacef as preferred preparations but therapeutic interchange rules apply during shortages.

Dosage Strategy

What dose should be prescribed for common conditions and how should it be adjusted?

For mild adult infections the standard oral dose is 250 mg twice daily.

For more severe ENT or respiratory infections and for early Lyme disease the usual adult oral dose is 500 mg twice daily for 14–21 days as indicated.

Intravenous dosing for severe systemic infections is commonly 750 mg to 1.5 g every eight hours.

Paediatric dosing is weight‑based, typically 10–15 mg/kg twice daily depending on indication and age.

Tonsillitis and sinusitis are usually treated with 250 mg twice daily for five to ten days.

Otitis media and pneumonia are commonly managed with 250–500 mg twice daily for seven to ten days.

Skin and soft‑tissue infections are typically 250–500 mg twice daily for seven to ten days.

For gonorrhoea, historical guidance lists 1.5 g intramuscular single dose, though this is now less commonly used.

Renal impairment requires dose reduction or extended dosing intervals, for example halving dose when CrCl <30 mL/min as a practical check.

Elderly patients require renal assessment before high doses, and hepatic impairment usually does not require adjustment unless severe.

Advise patients that cefuroxime axetil absorption is reduced by antacids and that tablets are best taken with food to improve bioavailability.

Safety Protocols

When should cefuroxime be avoided and what monitoring is needed?

Absolute contraindications include known allergy to cefuroxime or other cephalosporins and a history of immediate‑type hypersensitivity to beta‑lactams.

Caution is required in patients with a history of severe penicillin anaphylaxis because of possible cross‑reactivity.

Relative concerns include severe renal impairment and prior Clostridioides difficile colitis.

Common adverse effects are gastrointestinal symptoms such as diarrhoea, nausea and abdominal pain.

Skin reactions including rash and urticaria are also reported and should prompt review.

Rare laboratory findings include a positive Coombs test and asymptomatic haemolysis in isolated cases.

Serious but uncommon events reported are C. difficile infection and severe hypersensitivity including anaphylaxis.

Seizures may occur with overdose or marked renal impairment and require urgent management.

Before high‑dose or IV therapy check renal function and review concomitant nephrotoxins such as aminoglycosides.

Counsel patients to stop the drug and seek urgent assessment for signs of severe allergy or severe diarrhoea.

Interaction Mapping

Which substances change cefuroxime absorption or levels, and what should be avoided?

Food affects cefuroxime axetil: absorption is improved with food, so tablets are best taken with a meal.

Antacids, H2 antagonists and proton pump inhibitors can reduce absorption when taken at the same time.

Advise patients to space antacid or PPI use away from oral cefuroxime dosing when possible.

Probenecid reduces renal tubular secretion and increases plasma cefuroxime concentrations, which may be clinically relevant.

Concurrent use with nephrotoxic drugs such as aminoglycosides or high‑dose diuretics requires close renal monitoring.

Combining cefuroxime with other beta‑lactams offers no therapeutic benefit and increases the risk of allergic reactions.

For UK prescribers always check the full medication history, including OTC antacids, before starting cefuroxime axetil.

Adjust counselling and monitoring in the elderly and those with reduced renal clearance to reduce interaction risk.

Patient Experience Analysis

What do patients report about symptom relief and tolerability with cefuroxime?

Survey data from primary care and ambulatory settings indicate high satisfaction when cefuroxime is prescribed appropriately for otitis and sinusitis.

Patients commonly report good symptom resolution with oral therapy rather than injections when clinically suitable.

Tolerability is generally rated favourably, although gastrointestinal side effects are the most frequent complaint.

Forum conversations often mention brand names such as Zinnat and questions about switching from IV Zinacef to oral Zinnat.

Common patient themes include concerns about course length, allergy status and the need to finish the prescribed course.

Practical pharmacy actions include providing an NHS‑aligned patient leaflet, explaining missed‑dose actions and warning signs for adverse effects.

Documenting counselling on antacid timing, food with dosing and when to seek help improves adherence and safety.

Clinicians should record prior antibiotic reactions and check for penicillin allergy before prescribing any cephalosporin.

Distribution And Pricing Landscape

How available is cefuroxime and what should pharmacists expect on procurement?

Cefuroxime is widely available in the UK in both NHS and private markets under brand names Zinnat and Zinacef and as generics.

GlaxoSmithKline historically supplies Zinnat and Zinacef, while several generic manufacturers supply alternative preparations.

Common pack sizes include 125 mg, 250 mg and 500 mg tablets and 750 mg and 1.5 g IV vials.

NHS procurement typically favours cost‑effective generics via tendering, although some formularies still specify branded products.

Injection vials need protection from heat and light during transport and reconstituted suspension has a ten‑day refrigerated shelf life.

Pharmacy departments should follow cold‑chain standard operating procedures for reconstituted products and track expiry and lot numbers.

Occasional shortages occur and trusts often have therapeutic interchange policies to manage supply issues.

In our online pharmacy, cefuroxime is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

Patients and prescribers should always follow local formulary recommendations and stewardship policies when selecting products.

Alternative Options

Which antibiotics are reasonable alternatives and when should they be used instead?

Amoxicillin‑clavulanate offers broader beta‑lactamase coverage and is often preferred where anaerobic or extended beta‑lactamase activity is suspected.

Cefixime is a third‑generation cephalosporin with better activity for uncomplicated gonorrhoea but less streptococcal activity compared with cefuroxime.

Cefaclor is another second‑generation cephalosporin with a similar spectrum but is less commonly used in current practice.

Cefuroxime’s advantages include balanced Gram‑positive and Gram‑negative activity, oral and IV options, and an established safety profile.

Limitations include reduced activity against some resistant Gram‑negative organisms and absorption considerations with oral axetil in the presence of antacids.

Choose amoxicillin‑clavulanate when beta‑lactamase producers or anaerobic coverage are a concern and consult local susceptibility patterns.

For penicillin‑allergic patients with immediate‑type reactions, select a non‑beta‑lactam class and consider allergy testing where appropriate.

Always align antibiotic choice with local antimicrobial stewardship guidance and documented susceptibilities.

Regulatory Status

What is the regulatory position and how should adverse events be reported?

Cefuroxime products such as Zinnat and Zinacef are authorised across EU markets and are marketed in the UK.

Post‑Brexit, the Medicines and Healthcare products Regulatory Agency (MHRA) manages UK licensing and pharmacovigilance activities.

The product is classified as prescription‑only in nearly all markets according to available registrations.

In other territories such as the USA, cefuroxime is marketed under brand names including Ceftin and Zinacef and carries Rx status.

Ophthalmic intracameral cefuroxime is an established formulation where licensed for intraocular prophylaxis.

Report serious or unexpected reactions such as C. difficile or anaphylaxis to the MHRA Yellow Card scheme in the UK.

Local trust formularies and NICE recommendations should be consulted for approved indications, dosing and stewardship considerations.

Consolidated FAQ

Is cefuroxime safe in pregnancy?

Use only when clearly indicated after a risk–benefit assessment, as pregnancy and lactation require individual consideration.

Can penicillin‑allergic patients take cefuroxime?

Avoid cefuroxime in patients with a history of immediate‑type penicillin anaphylaxis; consider allergy testing or an alternative class.

How should Zinnat tablets be taken?

Cefuroxime axetil tablets should be taken with food to maximise absorption and should not be taken simultaneously with antacids.

What if a dose is missed?

Take a missed dose as soon as remembered and do not double the next dose; skip if close to the next scheduled dose.

How long can a reconstituted suspension be stored?

Reconstituted oral suspension should be refrigerated and discarded after ten days.

When should medical attention be sought?

Seek urgent care for severe allergic reactions, marked worsening of infection or severe diarrhoea suggestive of C. difficile.

Visual Guide

What quick visuals help clinicians and patients administer cefuroxime correctly?

Key panels should show tablet versus suspension versus IV vial with clear strengths and storage icons.

Tablet strengths include 125 mg, 250 mg and 500 mg; vials are 750 mg and 1.5 g; intracameral is 1 mg per 0.1 ml.

Storage icons: tablets store at 15–25°C in a dry place; reconstituted suspension refrigerate and discard after ten days; vials protect from light and store below 25°C.

Administration Flowchart

Oral Versus IV Decision Points

Start IV for severe or systemically unwell patients and switch to oral Zinnat 250–500 mg twice daily when clinically stable.

Renal Dosing Quick‑Check

When To Halve Dose Or Extend Interval

Consider dose reduction or extended interval when CrCl is below 30 mL/min and monitor renal function during therapy.

Use NHS colours and brand identifiers on patient leaflets for easier recognition and adherence.

Storage And Transport

How should pharmacy teams store and transport cefuroxime products?

Film‑coated tablets should be stored at room temperature between 15–25°C in a dry place.

Reconstituted oral suspension must be refrigerated and discarded after ten days.

Injection vials should be stored below 25°C and protected from light, with reconstituted solutions used promptly.

Maintain the cold chain for reconstituted suspensions during transport and follow NHS cold‑chain SOPs for injectable products.

Pharmacies should label reconstituted medicines with preparation and discard times and advise patients on fridge storage at home.

Document lot numbers and expiry dates and follow therapeutic interchange protocols during supply shortages.

Ensure staff are trained on handling vials and on safe disposal of unused antibiotics to reduce environmental risk.

Guidelines For Proper Use

What stewardship checks ensure cefuroxime is used correctly?

Prescribe cefuroxime according to local susceptibility patterns and national guidance such as NICE and MHRA recommendations.

Prefer targeted therapy and avoid broad empirical use when a narrower spectrum agent will suffice.

Pre‑Prescription

Confirm Indication, Allergy History, Renal Function

Check for documented penicillin or cephalosporin allergy and establish eGFR before initiating high‑dose or IV therapy.

During Therapy

Monitor Response, Adverse Effects, Signs Of C. Difficile

Assess clinical response regularly and switch IV to oral when the patient is stable, using Zinnat oral formulations for step‑down therapy.

Post‑Prescription

Document, Report Adverse Events, Review Duration

Report serious or unexpected reactions via the Yellow Card scheme and review duration with a preference for the shortest effective course where evidence allows.

Patient counselling should cover taking oral axetil with food, avoiding antacids at the same time, completing the course and seeking help for rash or severe diarrhoea.

Delivery Across United Kingdom